Related Experiment Videos
Pharmacologic prevention of acute ischemic complications of coronary angioplasty
1Cardiothoracic Unit, Northern General Hospital National Health Service Trust, Sheffield, United Kingdom.
Insights
Newer antiplatelet agents, like c7E3 Fab, show promise in preventing acute coronary occlusion after percutaneous transluminal coronary angioplasty (PTCA). These drugs target platelet aggregation, reducing cardiac events and mortality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary occlusion remains a significant risk post-percutaneous transluminal coronary angioplasty (PTCA), despite traditional anticoagulants like heparin and aspirin.
- Intracoronary thrombus formation is a key factor in abrupt vessel closure, necessitating improved preventive strategies.
Purpose of the Study:
- To review pharmacologic agents for preventing and treating acute ischemic complications associated with PTCA.
- To highlight newer strategies beyond traditional heparin and aspirin use.
Main Methods:
- Review of existing literature on anticoagulant and antiplatelet agents used in PTCA.
- Analysis of clinical trial data for various pharmacologic interventions.
Main Results:
- Traditional agents like heparin and aspirin have limitations in reducing PTCA-related risks.
- Newer agents, including direct thrombin inhibitors and the glycoprotein IIb/IIIa inhibitor c7E3 Fab, show potential.
- c7E3 Fab demonstrated significant reductions in 30-day mortality and cardiac events, with sustained benefits at 6 months.
Conclusions:
- Novel antiplatelet agents, particularly c7E3 Fab, offer improved outcomes in preventing acute ischemic complications after PTCA.
- c7E3 Fab's inhibition of the final common pathway of platelet aggregation may have lasting effects, potentially impacting restenosis.
Abstract:
The risk of acute coronary occlusion following percutaneous transluminal coronary angioplasty (PTCA) has remained high despite the traditional use of heparin and aspirin. Interest has focused on newer strategies for preventing intracoronary thrombus formation, which is an important mechanism of abrupt vessel closure. Pretreatment with thrombolytic agents has failed vigorous testing in double-blind trials. Retrospective and observational studies have indicated that pretreatment with intravenous heparin is of benefit in patients with unstable symptoms, but prolonged infusion after angioplasty increases bleeding complications without improving outcomes. Subcutaneous heparin may be safer, but has not proved more effective. Oral dipyridamole has shown no advantage over aspirin, although there is evidence to suggest a benefit when given intravenously. Direct thrombin inhibitors (such as hirudin and hirulog) are associated with fewer early complications compared with heparin, but have yielded no apparent long-term benefit. The use of the antiplatelet drug ticlopidine is increasing, although long-term data are lacking. A great deal of recent interest has focused on newer antiplatelet agents, particularly the glycoprotein IIB/IIIa receptor inhibitor c7E3 Fab. In a large-scale trial, c7E3 significantly reduced the 30-day rate of mortality and cardiac events, and these benefits were maintained at 6 mo. This drug, unlike other antiplatelet agents, inhibits the final common pathway of platelet aggregation, which influences not only acute closure but has lasting effects for at least 6 mo. This may reflect a reduction in restenosis, although this remains to be proven. This article gives a brief overview of the pharmacologic agents available for the prophylaxis and treatment of acute ischemic complications of PTCA.